Sapablursen

Generic Name: Sapablursen

Brand Names: -

Drug Type: Biotech

Chemical Formula: -

CAS Number: 2273007-95-5

Unique Ingredient Identifier: DXS4HJC32N

Background: Sapablursen is a synthetic 2'-O-(2-methoxyethyl)-modified antisense oligonucleotide linked to a tri-antennary cluster of N-acetyl galactosamine (GalNAc3) sugars targeting transmembrane protease, serine 6 messenger ribonucleic acid

Associated Conditions: -

Associated Therapies: -

Clinical Trials

A Study to Evaluate Sapablursen (Formerly ISIS 702843, IONIS-TMPRSS6-LRx) in Patients With Polycythemia Vera

Phase 2

Active, not recruiting

Conditions: Phlebotomy Dependent Polycythemia Vera

Interventions: Drug: sapablursen

First Posted Date: 2021-12-03

Last Posted Date: 2024-12-16

Lead Sponsor: Ionis Pharmaceuticals, Inc.

Target Recruit Count: 50

Registration Number: NCT05143957

Locations: 🇺🇸
O'Neal Comprehensive Cancer Center University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸
Mayo Clinic Hospital, Phoenix, Arizona, United States
🇺🇸
UCLA Health - Beverly Hills Cancer Care, Beverly Hills, California, United States

and more 24 locations

Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Sapablursen (Formerly ISIS 702843, IONIS-TMPRSS6-LRx)

Phase 2

Terminated

Conditions: Beta Thalassemia Intermedia

Interventions: Drug: sapablursen

First Posted Date: 2019-08-16

Last Posted Date: 2024-03-04

Lead Sponsor: Ionis Pharmaceuticals, Inc.

Target Recruit Count: 29

Registration Number: NCT04059406

Locations: 🇬🇷
Aghia Sophia General Children's Hospital, Athens, Attica, Greece
🇦🇺
Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia
🇦🇺
Monash Medical Centre, Clayton, Victoria, Australia

and more 16 locations

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 702843 Administered Subcutaneously to Healthy Volunteers

Phase 1

Completed

Conditions: Thalassemia

Interventions: Other: Placebo
Drug: IONIS TMPRSS6-Lrx

First Posted Date: 2017-05-24

Last Posted Date: 2019-01-22

Lead Sponsor: Ionis Pharmaceuticals, Inc.

Target Recruit Count: 36

Registration Number: NCT03165864

Locations: 🇦🇺
Nucleus Network, Melbourne, Victoria, Australia

Prev
1
Next

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy